ATR — AptarGroup, Inc.

Summary of Aptar's Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Adjusted Earnings Per Share (EPS): $1.62, up 4% year-over-year.
• Reported Sales: Increased by 6%, while core sales (adjusted for currency and acquisitions) grew by 1%.
• Adjusted EBITDA: Increased by 7% to $624 million, with a margin of 23.2%, up 30 basis points year-over-year.
• Net Income: Impacted by a $27 million gain from the remeasurement of a minority interest and $4 million in atypical litigation costs.
• Free Cash Flow: $206 million year-to-date, a decline attributed to higher working capital and pension contributions.
• Balance Sheet: Cash and short-term investments of $265 million, net debt of $936 million, and a leverage ratio of 1.22.

2. Strategic Updates and Business Highlights

• Pharma Segment: Strong demand for proprietary drug delivery systems, particularly in CNS therapeutics, asthma, and COPD. Core sales increased by 2%, with injectables up 18%.
• Acquisition: Agreement to acquire Sommaplast, enhancing Aptar's presence in Brazil's oral dosing market.
• Beauty Segment: Revenue growth in Asia and Latin America, but flat sales in Europe due to softness in high-value products. Personal Care grew by 11%.
• Closures Segment: Core sales decreased by 1%, impacted by lower tooling sales despite product volume growth.
• Innovation: Launch of several new technologies, including a proprietary nasal drug delivery system and a Bluetooth-enabled inhaler sensor.

3. Forward Guidance and Outlook

• Q4 2025 EPS Guidance: Expected to be in the range of $1.20 to $1.28.
• Pharma Growth: Continued strength anticipated, particularly in injectables, but offset by expected softness in emergency medicine.
• Long-term Growth Targets: Reaffirmed 7% to 11% growth for Pharma, driven by a stable pipeline and new product launches.
• Emergency Medicine: Anticipated revenue contribution for 2025 to be about 5% of total sales, with a significant decline expected in 2026.

4. Bad News, Challenges, or Points of Concern

• Consumer Healthcare: Down 11% due to destocking and lower sales of cough and cold products.
• Emergency Medicine: Facing headwinds with expected revenue decline of approximately 35% in 2026 due to inventory normalization at a large customer.
• Beauty Segment Margins: Continued pressure with flat core sales and a decline in adjusted EBITDA margin to 12.1%.
• Litigation Costs: Ongoing litigation related to pharma IP, resulting in atypical costs impacting net income.

5. Notable Q&A Insights

• Emergency Medicine Outlook: Analysts inquired about the significant decline expected in emergency medicine sales and the potential for recovery in 2027. Management indicated a return to low to mid-single-digit growth post-2026, contingent on stable government funding.
• GLP-1 and Annex 1 Contributions: Management confirmed GLP-1 as a key growth driver, with year-to-date growth rates exceeding 40%.
• Beauty Segment Strategy: Management emphasized the need for volume growth and highlighted ongoing efforts to improve operational efficiency and competitiveness.
• Litigation Cost Clarification: Management noted that litigation costs were atypical and not reflective of underlying business performance, providing transparency around their impact on financials.

Overall, Aptar reported solid third-quarter results, driven by strong performance in the Pharma segment, while facing challenges in Consumer Healthcare and Beauty. The company remains focused on strategic growth initiatives and shareholder returns despite anticipated headwinds in certain markets.